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With the advent and stunning success of combination antiretroviral therapy (ART) to prolong 
and improve quality of life for persons with HIV infection, HIV research has been afforded the 
opportunity to pivot towards studies aimed at finding “a cure.” The mere idea that cure of HIV 
might be possible has energized researchers and the community towards achieving this goal. 
Funding agencies, both governmental and private, have targeted HIV cure as a high priority; 
many in the field have responded to these initiatives and the cure research agenda is robust.
In this “salon” two editors of Pathogens and Immunity, Michael Lederman and Daniel Douek ask 
whether curing HIV is a realistic, scalable objective. We start with an overview perspective and 
have asked a number of prominent HIV researchers to add to the discussion. 
How things have changed: Once HIV was identified as the causative agent of AIDS, rapid de-
velopment of diagnostic tests for infection and development of drugs capable of blocking HIV 
replication shaped the clinical care agenda and altered progressively the landscape of infection. 
Now, in principle, HIV replication can be contained, allowing preservation or restoration of 
functional immune competence in most infected persons. Most HIV researchers and clinicians 
believed that cure of infection was not plausible and, therefore, did not merit further exploration. 
This perspective was turned around by the remarkable report [1] that an HIV-infected person 
undergoing treatment for leukemia in Berlin was cured of his infection (and his leukemia) after 
allogeneic hematopoietic progenitor cell transplantation from a donor homozygous for a defective 
HIV coreceptor gene—CCR5 Δ32. 
Since then, the landscape has changed. HIV cure has become a key priority for AIDS researchers, 
for both governmental and charitable funders, and for persons living with HIV infection. Among 
all this optimism, a variety of radically different approaches have been proposed to eliminate 
infection; yet, and although the field is very young, the “Berlin Patient” remains the only person 
to have been cured. Notably, a small number of cases that have attempted to replicate that result 
have failed [2].
Complete HIV eradication will not be simple and may not even be possible: The barriers to 
complete HIV elimination are substantial. Virus quiescence in host cell genomes renders infected 
cells not readily visible to host defenses; moreover the frequency of HIV-specific CD8 T cells 
typically decreases as HIV antigen levels fall with ART and these cells often have an “exhausted” 
(or dysfunctional) phenotype [3, 4]. Infected cells are broadly distributed in numerous tissues, 
including sites that may be relatively inaccessible to host defenses or treatment strategies [5], and 
the limits of sampling render our best current assays for residual infectious virus incompletely 
sensitive to detection of viral persistence in these tissues [6]. Recognizing that complete 
eradication is a daunting objective that may not be readily scalable, affordable, or possible, some 
treatment strategies are proposing a less definitive outcome that has come to be called “functional 
cure”—broadly defined as a state in which ART may be withdrawn without subsequent virus 
recrudescence. The concept is akin to that of “complete remission” after treatment for malignant 
cancer.
Natural control of HIV infection: The plausibility of functional cure has been guided by the 
demonstration that certain rare HIV-infected persons, “elite controllers” can control viremia in 
the absence of antiretroviral therapy [7, 8]. More recently, studies of participants in the French 
Visconti cohort have suggested that some persons in whom ART is initiated early in the course of 
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infection can durably interrupt ART while sustaining virologic control [9]. While strategies capa-
ble of achieving this clinical phenotype can teach us a great deal about the determinants of host 
defense against HIV replication, this outcome, as currently understood, may not be as clinically 
beneficial as those that are already achievable with ART. 
Disease progression in elite controllers: While the elite controller state is associated with sus-
tained low levels of plasma viremia in the absence of antiretroviral therapy, indices of inflamma-
tion and coagulation are higher than among persons in whom HIV replication is controlled by 
ART [10]. Moreover, while progressive CD4 decline is rare in ART-controlled HIV infection (Be-
nigno Rodriguez, personal communication, August 2016), it does occur among elite controllers 
[11]. In part for these reasons, the AIDS Clinical Trials Group has launched a controlled clinical 
trial of ART in elite controllers to ascertain whether treatment affects the inflammatory and CD4 
T cell trajectory in these persons. 
With these issues in mind, is the goal of achieving functional cure as defined by elite controller 
status good enough? While this may not be a clinically desirable ultimate objective, strategies 
that result in “functional cure” could plausibly contribute to a multi-component regimen that 
might eradicate infection. Perhaps we should regard functional cure as an experimental target 
that may help to reveal the determinants of host control of HIV replication and its persistence. 
Treatment strategies designed to achieve a functional cure should include careful monitoring of 
inflammatory and procoagulant indices and, if these remain elevated, serve as a warning that the 
strategy alone may not be optimal. Nonetheless, strategies that induce control of HIV replication 
or that decrease the size of the HIV reservoir(s) could plausibly be part of more comprehensive 
approaches designed to completely eliminate (cure) HIV infection. Testing these strategies could 
clarify the roles of the mechanisms induced or targeted in HIV replication and persistence and, as 
such, have intrinsic value; whether they will alone confer clinical benefit comparable to or exceed-
ing that achieved by ART is another question entirely.
CHALLENGES TO “THE CURE”
Where does HIV persist? While the latently-infected CD4 T cell is the predominant “reservoir” 
of cells containing infectious virus, there may be others (such as macrophages), and infected cells 
of any type may be distributed in anatomical sites less reliably accessible to antiretroviral drugs 
[5]. These reservoirs need to be better understood, with the goal of defining how many potentially 
infectious viruses are present in an infected person whose viremia is “fully suppressed” by ART. 
We already recognize from experience with hematopoietic progenitor cell transplantation that 
virus can persist and reactivate despite levels in peripheral blood that escape our assay detection 
limits [6]. A single cell with an intact provirus may be enough to “ruin” an attempt at a cure. 
Quiescence is also a challenge to host immune defenses. Ongoing HIV replication promotes virus 
persistence through selection for resistance and escape from host defenses. Suppressive antiret-
roviral therapy will halt this evolutionary mechanism for virus survival, but the persistence of 
infectious virus genomes that are not expressing virus proteins allows these infected cells to serve 
as durable reservoirs of infectious virus that remain indifferent to any host defense that targets 
expressed virus elements. 
Targeting the HIV reservoir: Many novel strategies are being explored in an effort to complete-
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ly eradicate HIV infection. The majority will likely fail and, for the reasons outlined above, even 
those that reliably decrease the size of the HIV reservoir may be insufficient to cure HIV. We still 
do not have a sense that there exists a level of reservoir reduction—without complete elimina-
tion—that would suffice to result in durable control of HIV as defined by the absence of viremia. 
In this regard, the limits of our ability to monitor virus persistence make it impossible to know 
whether every infectious virus has been eliminated from the one person who has been cured. In 
the Berlin Patient, replacement of the entire immune cell pool with cells resistant to HIV likely 
rendered the emergence from latency of any residual infectious virus incapable of amplification. It 
remains to be seen whether HIV can be eradicated from any person without also rendering all or 
most of the host cellular targets for infection “resistant” to HIV.
Can the host be made resistant to HIV? A number of strategies are being explored that include 
introduction of resistance elements or gene editing to render immune cells resistant to HIV 
infection [12]. As noted, replacement of host immune cells with “naturally” HIV resistant allo-
geneic cells likely was a major determinant that led to the cure of the Berlin Patient. And while 
CCR5-deficient cells were apparently sufficiently resistant to infection with the viruses infecting 
this patient, it is not clear that this approach will be effective in all individuals, some of whom 
may harbor viruses capable of binding to other coreceptors, such as CXCR4 or others [13]. Thus, 
for some (or many), other resistance strategies will be necessary. Altering the nature of target 
host cells to render them HIV-resistant might work, but it remains to be seen whether a scalable 
strategy can be devised that can safely destroy and purge enough latently infected cells and safely 
replace enough of the HIV-susceptible target cell with resistant cells. Unknowns here include how 
much purging and how much replacement will be necessary to result in durable control of HIV 
replication. 
Will HIV cure normalize the perturbed immune homeostasis and the inflammatory/procoag-
ulant state of treated HIV infection? As noted above, many persons with ART-suppressed infec-
tion maintain low circulating CD4 T cell numbers, increased circulating CD8 T cell counts, and 
an increased proinflammatory and procoagulant state that have been linked to ART-era morbid-
ity and mortality [14-16]. Setting aside for the moment whatever costs there might be to the host 
of any plausible cure strategies, we should ask what would happen to these immune, inflammato-
ry, and coagulation abnormalities if all remaining HIV could be made to disappear? This “thought 
experiment” isn’t completely fanciful, as we must take into consideration the long-lasting effects 
that sustained periods of HIV replication and its consequences have had on immune and inflam-
matory homeostasis. Though the drivers and the mechanisms of these perturbations are incom-
pletely understood, persistent fibrosis and immune dysregulation are readily demonstrable in gut 
and lymphoid tissues in treated HIV infection and are linked to the immune restoration failure 
[17] and persistent systemic inflammation [18] that are both linked to ART-era morbidity [14, 
19]. Because it remains unclear whether these architectural residua of chronic infection will re-
solve with HIV eradication, we should be prepared to consider the possibility that they will not—
and explore strategies to correct them. 
Do we need a cure? Early ART was poorly tolerated, complicated, and far less effective than 
current combination regimens. These days, many persons with HIV infection can achieve durable 
control of HIV replication with once daily administration of well-tolerated single pill combina-
tion agents. Furthermore, those who start treatment early are likely to sustain normal circulating 
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CD4 T cell numbers, remain free of opportunistic infections, and have a predicted survival simi-
lar to that of uninfected persons [20]. Thus, the bar for a scalable cure strategy is high!
Community engagement: There is great community interest in HIV eradication and clinical 
studies that target HIV eradication are particularly attractive to many persons infected with HIV. 
It is important that these clinical trials don’t promise too much, and that they provide a realistic 
perspective on risks and plausible outcomes. 
Summary: There are numerous scientific, technical, and logistical challenges to curing HIV infec-
tion and the HIV research community is poised to address them. Will any of these strategies suc-
ceed in providing a scalable approach to HIV eradication in our lifetime? This remains to be seen, 
and how exactly does one define a lifetime? There are already an estimated 37 million HIV-infect-
ed persons worldwide who are in need of lifelong treatment. Now a key goal remains to deliver 
treatment to all who need it. And while there are formidable challenges to HIV eradication, there 
is much to be learned from cure trials that are creatively and thoughtfully designed.
COMMENTARIES
Paula Cannon
HIV infection is a failure of the immune response, even when supported by the most effective 
ART. Like a cancer escaping chemotherapy, it reflects the limitations of what we can do against 
this most insidious of human pathogens. But recent advances in cancer treatments have shown 
the potential of a smart(er) immune response and for HIV we can do the same. Gene therapy is 
providing the tools to act on the explosion of knowledge of immune responses that HIV research 
has itself contributed. We can manipulate cells to be both HIV resistant and more HIV respon-
sive. It is time to make these tweaks and stand back and let the immune system do the heavy 
lifting.
Judith Currier
Despite the significant challenges that lie ahead in the attempts to cure HIV, the path is worth 
pursuing for several reasons. First, if there is a cure down the road, it will likely work best for 
those who start treatment early. This adds yet another potential incentive for starting therapy as 
early as possible for those diagnosed with HIV. If more people start treatment early that will help 
to slow the epidemic and everyone benefits. Second, research towards a cure that includes care-
ful study of post-treatment controllers could shed light on key immunologic responses that can 
inform vaccine research. And finally, despite the improvements in therapy available in some parts 
of the world, many people living with HIV still hope that one day they will be free of the virus. 
Having one person cured is a strong gravitational force to keep us going down this path.
Carl June
I am not optimistic that immune and vaccine approaches will be sufficient for “cure” strategies, 
and that in cases where an “elite controller” status can be successfully induced, it will come at an 
unsustainable fitness cost to health in the form of inflammation and accelerated aging. On the 
other hand, I am optimistic that installing an HIV-resistant immune system using the principles 
of synthetic biology is possible. I am most optimistic regarding approaches that utilize engineered 
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HIV-resistant T cells and stem cells to phenocopy a graft vs leukemia effect (i.e., to purge endog-
enous CD4 T cells), and to use cellular host restriction factors to block infection. We have many 
new tools for genetic editing and cell engineering to accomplish the above. 
Hans Peter Kiem
I think there will be a cure for HIV but, just as with cancer, there will likely not be one magic 
treatment that will be a cure for all HIV patients. I believe 2 important issues must be addressed 
to facilitate HIV cure research. 1) Definition of HIV cure: Measuring complete HIV eradication 
is very difficult and may be impossible to accomplish in a timely fashion. When treating cancer, 
we talk about remission and long-term remission and then eventually about cure, a process that 
takes many, many years and in most cases at least 5 years of complete remission. However, func-
tional cure, that is, “a state in which ART may be withdrawn without subsequent virus recru-
descence” can easily be measured and studied and would allow us to evaluate novel, promising 
treatment strategies very quickly and efficiently, and we may be able to identify situations and 
mechanisms that lead to HIV eradication. 2) Taking advantage of novel immunotherapies: The 
recent enormous advances in using gene therapy/editing for immunotherapy in the cancer field to 
target specific cancer antigens will allow us to use this technology to target specific HIV antigens 
and combine this approach with other promising treatments such as the use of broadly neutral-
izing antibodies or vaccines. In addition, we can use the gene editing technology to render our 
immune system resistant to HIV infection, which will further boost the patient’s immune system 
to fight and control HIV infection. 
Daniel Kuritzkes
There is no guarantee that even if cure is achieved it will lessen the long-term consequences of 
having once been HIV infected, or that the inflammatory state will return to baseline. This re-
mains an untested hypothesis, and an important reality check.
Will approaches to cure be “scalable”? Clearly, this is an important issue for general implementa-
tion, but not essential for proof of concept. If an approach to cure can be found that is less drastic 
than what was applied in the case of the Berlin Patient, one could then work on refinements to 
make it scalable. Azidothymidine (AZT) administered Q4H was not really scalable, but we’ve 
moved on from there.
Do we need a cure? First we must acknowledge that whereas current treatment is highly effective, 
safe, and convenient, it nevertheless requires lifelong administration and reasonably strict adher-
ence. The question of the sustainability of providing lifelong ART to the 37 million in need is a 
worry. In addition, patients speak of the stigma of HIV infection, and the stigma associated with 
the need to take ART. I fully agree that community expectations must be managed realistically 
and we need to be careful not to over-promise; nevertheless, to some extent the groundswell of 
enthusiasm around cure research on the part of patients is motivated at least in part by the stig-
ma issue, and in part by unrealistic expectations about the state of health to which they might be 
restored absent HIV. 
Sharon Lewin
In the last 5 years, considerable progress has been made in understanding where HIV persists, 
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developing new methods to measure virus persistence, identifying relevant animal models, and 
defining what will be needed for an effective intervention. It is now clear that simply reducing 
persistent virus will not be sufficient. Long-term immune surveillance will also be critical to 
ensure that rebound virus doesn’t occur. I believe both strategies will be needed and both present 
unique challenges. Although treatment is now relatively simple and increasingly cheap, the global 
burden of maintaining lifelong treatment for all who need it, especially in low income countries, 
is formidable with respect to both cost and health infrastructure. Therefore, there is a high need 
for a continued concerted collaborative effort to find a way to safely stop ART and to ensure that 
the end product will be cheap, scalable, and available globally. 
David Margolis
“It is our task, both in science and in society at large, to prove the conventional wisdom wrong 
and to make our unpredictable dreams come true.” —Freeman Dyson
The many unknowns and challenges of research towards HIV remission or cure are well outlined 
here. Although it would not address the desires of most living with HIV infection, the argument 
could be made that the tools to eventually end AIDS by completely interrupting ongoing trans-
mission are already at hand. However, the true metrics of the events that drive persistent HIV 
infection or thwart its clearance—the lifespan of latently infected cells, the frequency with which 
new latent infections arise during suppressive therapy, the true efficiency of serial latency reversal 
therapy in vivo, and the effectiveness of natural or engineered antiviral clearance mechanisms—
have not been directly and precisely measured. Therefore it is impossible to know whether a cure 
is one breakthrough away or requires several decades of determined effort to be realized.
Mike McCune 
From the hallways of San Francisco General Hospital, reflecting on three-plus decades in the 
midst of the HIV epidemic, recalling the time when very few survived infection, I find it both re-
markable and inspiring to read a review such as this. Not only has the life expectancy of HIV-in-
fected individuals been extended from weeks to many years, the community is now envisioning a 
time—perhaps far off but nonetheless in focus—when there might be a safe, scalable, and afford-
able cure. Douek and Lederman discuss the allure of such a cure while also honestly revealing the 
barriers ahead. Such balance should help us to walk forward with purpose during the upcoming 
years—and to thoroughly test the possibility that a cure is possible. Whatever transpires, it is won-
derful to know that this effort is being tackled with such great thought and drive.
John Mellors
The remarkable success of current ART, which largely consists of a single tablet taken daily with 
minimal to no adverse effects, makes achieving sustained remission of HIV without ART a very 
daunting challenge. The safety and efficacy of current ART also lowers the tolerance that the 
scientific, regulatory, and patient communities will have for adverse consequences of therapies de-
signed to achieve an HIV cure. For these reasons, I believe the best opportunity to achieve a safe 
HIV remission is through the use of “designer” monoclonal antibodies that are generally very safe 
and that promote the clearance of HIV-infected cells through immune effector cells (phagocytes 
and NK cells) combined with therapeutic vaccines that induce broad, polyfunctional immune 
responses to highly conserved HIV epitopes, keeping virus in check that emerges from latency. 
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Other approaches including latency reversing agents, gene therapy, autologous hematopoietic 
transplantation, cellular therapy with modified T-cell receptors (e.g., CARs) and immune check-
point inhibition (e.g. anti-PD-1/PD-L1) all have higher inherent risks of toxicity, many of which 
may prove to be unacceptable in the context of currently safe, convenient, and very effective ART. 
It is also important to consider that the efficacy of any curative approach is likely to vary by the 
stage of HIV disease at which ART was started. If ART had been delayed until severe immuno-
deficiency was present, it is likely to be much more difficult to repair immune dysfunction and 
generate broad and effective HIV-specific immune responses than if ART had been started sooner 
after infection when immune damage was minimal. Early initiation of ART also has the major 
benefit of stopping HIV replication and evolution before a swarm of immune escape variants 
can emerge. Restricting the size and diversity of HIV reservoirs will reduce the number of viral 
variants that need to be controlled by antibody therapy and/or vaccination. For these reasons, if 
sustained remission of HIV can be achieved, it is most likely to occur first in individuals treated 
with ART at the earliest stages of infection, although this group represents a small proportion of 
individuals living with HIV infection. 
Timothy Schacker
HIV infected people on therapy are not immunologically normal, continue to have significant 
medical problems, and have early mortality. We know a cure is possible if we can find a way to 
recapitulate the steps that led to a cure in the Berlin Patient (first ablate the reservoir and then 
prevent its reestablishment) in a way that is safe and economically feasible. Immunotherapy for 
cancer is providing remarkable results in conditions that were otherwise lethal and may provide 
a strategy to eliminate virus-infected cells, thus ablating the reservoir. The field of gene therapy 
is advancing quickly and there are already clinical trials in HIV infection to provide cells that 
can’t get infected with HIV. These remarkable advances make me believe a cure is possible, but 
we should never lose sight of the fact that most people with the infection live in resource-limited 
settings where delivery of complex medical therapies is, at best, challenging. Having said that, I 
firmly believe we should be exploring all of these exciting opportunities, as I think it very likely 
they will eventually lead us to at least a functional, if not complete, cure.
Rafick Sekaly
Immune homeostasis, the process that leads to the maintenance of memory T cells and, by infer-
ence, the HIV reservoir is under the control of regulatory T cells and the cytokines they produce: 
TGF beta and IL-10. These cytokines are triggered in response to the proinflammatory environ-
ment that results from virus sensing by pattern recognition receptors and by bacterial transloca-
tion. They disrupt homeostasis by creating an environment of immune quiescence and immune 
senescence, which prevents the replacement of latently infected cells by new cells. This establishes 
the HIV reservoir. Resetting homeostasis through interventions that are less invasive than those 
that were administered to the Berlin Patient will help eradicate HIV. Controlling Treg function 
could be an easier fix than once thought. 
Pablo Tebas
Timothy Ray Brown [The Berlin Patient] proved that HIV can be eradicated in the same way 
that Neil Armstrong proved that humans can go to the moon. Sometimes in science you only 
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need n=1 experiments. I think we will reach first a functional cure: patients will not have to take 
antiretrovirals and will not have ongoing issues with HIV. I do not know if it will be with a ther-
apeutic vaccine, activators or inhibitors of the reservoir, immunomodulators, gene therapy, or a 
combination of these. Curing HIV will not be easy and might not happen often, but is it worth 
trying? Absolutely, because, to rephrase Judy Garland, “The dreams that we do not dare to dream 
really do not come true.”
Bruce Walker
The answer to whether we can cure HIV infection has to be yes. A single patient has proven this—
with the caveat that ongoing follow-up is still needed. If current paradigms hold, cure is not likely 
to happen soon, and scalability is an even greater reach. A major question is how to speed the dis-
covery process that is likely to be required to reliably achieve cure. Studying elite controllers and 
post-treatment controllers may provide insights, but a similar functional cure is unlikely to be a 
satisfactory outcome. Interventional studies in persons who are treated early in acute infection 
may represent a lower bar due to smaller reservoir size. Immune augmentation with vaccines or 
administration of broadly neutralizing antibodies may provide access to germinal center reser-
voirs, which may be the main drivers of persistence. The bottom line is, we still have a lot to learn.
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